Detalhe da pesquisa
1.
Trial designs and endpoints for immune therapies in multiple myeloma.
Am J Hematol
; 98 Suppl 2: S35-S45, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200130
2.
The effect of novel therapies in high-molecular-risk multiple myeloma.
Clin Adv Hematol Oncol
; 15(11): 870-879, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29200420
3.
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Ann Hematol
; 100(12): 3057-3060, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33009581
4.
Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens.
Am J Hematol
; 89(6): 616-20, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24616227
5.
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 24(1): 32-39, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37783639
6.
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
J Immunother Cancer
; 12(4)2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609316
7.
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Blood Adv
; 8(1): 236-247, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772981
8.
Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma.
Dermatopathology (Basel)
; 10(3): 226-230, 2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37489455
9.
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
Bone Marrow Transplant
; 58(1): 80-86, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261708
10.
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Blood Cancer Discov
; 4(6): 440-451, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769148
11.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Blood Adv
; 7(6): 1056-1064, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36018226
12.
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma.
NPJ Genom Med
; 8(1): 3, 2023 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702834
13.
Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35190376
14.
High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
Clin Lymphoma Myeloma Leuk
; 22(11): 853-862, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35945129
15.
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(3): 192-197, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34736880
16.
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
JCO Precis Oncol
; 6: e2200147, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35704796
17.
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
Nat Commun
; 13(1): 3750, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35768438
18.
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Blood Cancer Discov
; 3(4): 273-284, 2022 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653112
19.
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.
Cancer Res Commun
; 2(10): 1255-1265, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36969740
20.
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
Expert Rev Hematol
; 14(1): 31-45, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33331794